Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All budesonide studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchBudesonideBudesonide (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The relationship between oxygen therapy, drug therapy, and COVID-19 mortality

Yang et al., Open Medicine, doi:10.1515/med-2022-0569
Aug 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -11% Improvement Relative Risk Budesonide for COVID-19  Yang et al.  LATE TREATMENT Is late treatment with budesonide beneficial for COVID-19? Retrospective 185 patients in China (January - February 2020) No significant difference in mortality c19early.org Yang et al., Open Medicine, August 2022 Favorsbudesonide Favorscontrol 0 0.5 1 1.5 2+
Budesonide for COVID-19
19th treatment shown to reduce risk in April 2021
 
*, now with p = 0.0000011 from 15 studies, recognized in 8 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19early.org
Retrospective 185 hospitalized COVID-19 patients in China, showing no significant difference in mortality with budesonide use in unadjusted results.
Targeted administration to the respiratory tract provides treatment directly to the typical source of initial SARS-CoV-2 infection and replication, and allows for rapid onset of action, higher local drug concentration, and reduced systemic side effects (early treatment may be more beneficial).
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 10.8% higher, RR 1.11, p = 0.85, treatment 30 of 125 (24.0%), control 13 of 60 (21.7%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Yang et al., 31 Aug 2022, retrospective, China, peer-reviewed, median age 62.0, 12 authors, study period 1 January, 2020 - 29 February, 2020. Contact: 2205603@tongji.edu.cn, 1220775601@qq.com, 29553185@qq.com.
This PaperBudesonideAll
The relationship between oxygen therapy, drug therapy, and COVID-19 mortality
Ling Yang, Guoxi Chen, Yuyang Cai, Ye An, Xiaopan Li, Ying Chen, Cheng Xu, Chen Ji, Xing Lan, Yaling Wang, Hai Huang, Li Han
Open Medicine, doi:10.1515/med-2022-0569
Since December, 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 . We conducted a retrospective study of COVID-19 inpatients in Wuhan Pulmonary Hospital (Wuhan, China) from January 1 to February 29, 2020. The subjects were divided into four groups due to different treatment regimes. We used the Kaplan-Meier method to determine the cumulative rates of in-hospital death and the Cox proportional hazard model to calculate the risk factors and corresponding hazard ratios. A total of 185 patients were included in this study. The median age of the patients was 62 years, including 94 men and 91 women. Kaplan-Meier analysis demonstrated that mortality was higher in older patients, higher in men, and lower in the low-flow oxygen therapy group. Body mass index (BMI) had no influence on mortality, as well as high flow oxygen therapy, Lopinavir-ritonavir (LPV/r) therapy, and the interferon-alpha add LPV/r therapy. Cox proportional hazard regression confirmed that the low flow oxygen therapy was independent protective factor for in-hospital death after adjusting for age, gender, and BMI. In conclusion, the mortality was higher in older patients, higher in men, and lower in the low-flow oxygen therapy group. BMI had no influence on mortality, as well as high flow oxygen therapy, LPV/r therapy, and interferon-alpha add LPV/r therapy.
Abbreviations Conflict of interest: The authors declare that they have no competing interest.
References
Cao, Wang, Wen, Liu, Wang et al., A Trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19, N Engl J Med, doi:10.1056/NEJMoa2001282.Epub2020
Holshue, Debolt, Lindquist, Lofy, Wiesman et al., First case of 2019 novel coronavirus in the United States, N Engl J Med, doi:10.1056/NEJMoa2001191.Epub2020
Li, Guan, Wu, Wang, Zhou et al., Early transmission dynamics in Wuhan, China, of novel coronavirusinfected pneumonia, N Engl J Med, doi:10.1056/NEJMoa2001316.Epub2020
Mo, Xing, Xiao, Deng, Zhao et al., Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China, Clin Infect Dis, doi:10.1093/cid/ciaa270
Wang, Pan, Tan, Xu, Ho, Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China, Int J Environ Res Public Health, doi:10.3390/ijerph17051729
Wenham, Smith, Morgan, COVID-19: the gendered impacts of the outbreak, Lancet, doi:10.1016/s0140-6736(20)30526-2.Epub2020
Wu, Liu, Zhao, Liu, Wang, Clinical characteristics of imported cases of COVID-19 in Jiangsu Province: a multicenter descriptive study, Clin Infect Dis, doi:10.1093/cid/ciaa199
Zeng, Xu, He, Tang, Li et al., Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia, Chin Med J, doi:10.1097/CM9.0000000000000790
Zhao, Cao, Chong, Gao, Lou et al., The timevarying serial interval of the coronavirus disease (COVID-19) and its gender-specific difference: A data-driven analysis using public surveillance data in Hong Kong and Shenzhen, China from January 10 to, Infect Control Hospital Epidemiol, doi:10.1017/ice.2020.64
Zhu, Zhang, Li, Yang, Song, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med, doi:10.1056/NEJMoa2001017.Epub2020
{ 'indexed': {'date-parts': [[2022, 12, 7]], 'date-time': '2022-12-07T06:01:23Z', 'timestamp': 1670392883193}, 'reference-count': 12, 'publisher': 'Walter de Gruyter GmbH', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2022, 1, 1]], 'date-time': '2022-01-01T00:00:00Z', 'timestamp': 1640995200000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2022, 11, 22]]}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:p>Since December, 2019, Wuhan, China, has experienced an outbreak of ' 'coronavirus disease 2019 (COVID-19). We conducted a retrospective study of COVID-19 ' 'inpatients in Wuhan Pulmonary Hospital (Wuhan, China) from January 1 to February 29, 2020. ' 'The subjects were divided into four groups due to different treatment regimes. We used the ' 'Kaplan–Meier method to determine the cumulative rates of in-hospital death and the Cox ' 'proportional hazard model to calculate the risk factors and corresponding hazard ratios. A ' 'total of 185 patients were included in this study. The median age of the patients was 62 ' 'years, including 94 men and 91 women. Kaplan–Meier analysis demonstrated that mortality was ' 'higher in older patients, higher in men, and lower in the low-flow oxygen therapy group. Body ' 'mass index (BMI) had no influence on mortality, as well as high flow oxygen therapy, ' 'Lopinavir–ritonavir (LPV/r) therapy, and the interferon-alpha add LPV/r therapy. Cox ' 'proportional hazard regression confirmed that the low flow oxygen therapy was independent ' 'protective factor for in-hospital death after adjusting for age, gender, and BMI. In ' 'conclusion, the mortality was higher in older patients, higher in men, and lower in the ' 'low-flow oxygen therapy group. BMI had no influence on mortality, as well as high flow oxygen ' 'therapy, LPV/r therapy, and interferon-alpha add LPV/r therapy.</jats:p>', 'DOI': '10.1515/med-2022-0569', 'type': 'journal-article', 'created': { 'date-parts': [[2022, 11, 22]], 'date-time': '2022-11-22T14:25:57Z', 'timestamp': 1669127157000}, 'page': '1833-1839', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'The relationship between oxygen therapy, drug therapy, and COVID-19 mortality', 'prefix': '10.1515', 'volume': '17', 'author': [ { 'given': 'Ling', 'family': 'Yang', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Geriatrics, Shanghai Fourth People’s Hospital ' 'Affiliated to Tongji University , Shanghai , China'}]}, { 'given': 'Guoxi', 'family': 'Chen', 'sequence': 'additional', 'affiliation': [ { 'name': 'Tuberculosis department, Wuhan Pulmonary Hospital , Wuhan , ' 'China'}]}, { 'given': 'Yuyang', 'family': 'Cai', 'sequence': 'additional', 'affiliation': [ { 'name': 'School of Public Health, Shanghai Jiaotong University School of ' 'Medicine , Shanghai , China'}]}, { 'given': 'Ye', 'family': 'An', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Geriatrics, Shanghai Jiaotong University School of ' 'Medicine, Xinhua Hospital , Shanghai , China'}]}, { 'given': 'Xiaopan', 'family': 'Li', 'sequence': 'additional', 'affiliation': [ { 'name': 'Pudong Institute of Preventive Medicine, Fudan University , ' 'Shanghai , China'}]}, { 'given': 'Ying', 'family': 'Chen', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Geriatrics, Shanghai Jiaotong University School of ' 'Medicine, Xinhua Hospital , Shanghai , China'}]}, { 'given': 'Cheng', 'family': 'Xu', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Geriatrics, Shanghai Jiaotong University School of ' 'Medicine, Xinhua Hospital , Shanghai , China'}]}, { 'given': 'Chen', 'family': 'Ji', 'sequence': 'additional', 'affiliation': [ { 'name': 'Warwick Clinical Trials Unit, Warwick Medical School , Warwick , ' 'Great Britain'}]}, { 'given': 'Xing', 'family': 'Lan', 'sequence': 'additional', 'affiliation': [ { 'name': 'Tuberculosis department, Wuhan Pulmonary Hospital , Wuhan , ' 'China'}]}, { 'given': 'Yaling', 'family': 'Wang', 'sequence': 'additional', 'affiliation': [ { 'name': 'Tuberculosis department, Wuhan Pulmonary Hospital , Wuhan , ' 'China'}]}, { 'given': 'Hai', 'family': 'Huang', 'sequence': 'additional', 'affiliation': [ { 'name': 'Tuberculosis department, Wuhan Pulmonary Hospital , Wuhan , ' 'China'}]}, { 'given': 'Li', 'family': 'Han', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Geriatrics, Shanghai Jiaotong University School of ' 'Medicine, Xinhua Hospital , Shanghai , China'}]}], 'member': '374', 'published-online': {'date-parts': [[2022, 11, 22]]}, 'reference': [ { 'key': '2022120618374797156_j_med-2022-0569_ref_001', 'unstructured': 'Chinese researchers reveal draft genome of virus implicated in Wuhan ' 'pneumonia outbreak. ' '(https://www.sciencemag.org/news/2020/01/chinese-researchers-reveal-draft-genome-virus-implicated-wuhan-pneumonia-outbreak).'}, { 'key': '2022120618374797156_j_med-2022-0569_ref_002', 'doi-asserted-by': 'crossref', 'unstructured': 'Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus ' 'from patients with pneumonia in China, 2019. N Engl J Med. ' '2020;382:727–33. 10.1056/NEJMoa2001017.Epub2020.', 'DOI': '10.1056/NEJMoa2001017'}, { 'key': '2022120618374797156_j_med-2022-0569_ref_003', 'unstructured': 'WHO Director-General’s Remarks at the Media Briefing on 2019-nCoV on 11 ' 'February 2020. ' '(https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020).'}, { 'key': '2022120618374797156_j_med-2022-0569_ref_004', 'doi-asserted-by': 'crossref', 'unstructured': 'Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission ' 'dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N ' 'Engl J Med. 2020;382(13):1199–207. 10.1056/NEJMoa2001316.Epub2020.', 'DOI': '10.1056/NEJMoa2001316'}, { 'key': '2022120618374797156_j_med-2022-0569_ref_005', 'doi-asserted-by': 'crossref', 'unstructured': 'Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. ' 'First case of 2019 novel coronavirus in the United States. N Engl J Med. ' '2020;382(10):929–36. 10.1056/NEJMoa2001191.Epub2020.', 'DOI': '10.1056/NEJMoa2001191'}, { 'key': '2022120618374797156_j_med-2022-0569_ref_006', 'doi-asserted-by': 'crossref', 'unstructured': 'Zeng YM, Xu XL, He XQ, Tang SQ, Li Y, Huang YQ, et al. Comparative ' 'effectiveness and safety of ribavirin plus interferon-alpha, ' 'lopinavir/ritonavir plus interferon-alpha and ribavirin plus ' 'lopinavir/ritonavir plus interferon-alphain in patients with mild to ' 'moderate novel coronavirus pneumonia. Chin Med J. 2020;133(9):1132–4. ' '10.1097/CM9.0000000000000790.', 'DOI': '10.1097/CM9.0000000000000790'}, { 'key': '2022120618374797156_j_med-2022-0569_ref_007', 'doi-asserted-by': 'crossref', 'unstructured': 'Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of ' 'Lopinavir–Ritonavir in adults hospitalized with severe Covid-19. N Engl ' 'J Med. 2020;382(19):1787–99. 10.1056/NEJMoa2001282.Epub2020.', 'DOI': '10.1056/NEJMc2008043'}, { 'key': '2022120618374797156_j_med-2022-0569_ref_008', 'doi-asserted-by': 'crossref', 'unstructured': 'Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical ' 'characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin ' 'Infect Dis. 2020;73(11):e4208–213. 10.1093/cid/ciaa270.', 'DOI': '10.1093/cid/ciaa270'}, { 'key': '2022120618374797156_j_med-2022-0569_ref_009', 'doi-asserted-by': 'crossref', 'unstructured': 'Wang C, Pan R, Wan X, Tan Y, Xu L, Ho C, et al. Immediate psychological ' 'responses and associated factors during the initial stage of the 2019 ' 'coronavirus disease (COVID-19) epidemic among the general population in ' 'China. Int J Environ Res Public Health. 2020;17(5):1729. ' '10.3390/ijerph17051729.', 'DOI': '10.3390/ijerph17051729'}, { 'key': '2022120618374797156_j_med-2022-0569_ref_010', 'doi-asserted-by': 'crossref', 'unstructured': 'Wenham C, Smith J, Morgan R. COVID-19: the gendered impacts of the ' 'outbreak. Lancet (London, Engl). 2020;395:846–8. ' '10.1016/s0140-6736(20)30526-2.Epub2020.', 'DOI': '10.1016/S0140-6736(20)30526-2'}, { 'key': '2022120618374797156_j_med-2022-0569_ref_011', 'doi-asserted-by': 'crossref', 'unstructured': 'Zhao S, Cao P, Chong MK, Gao D, Lou Y, Ran J, et al. The time-varying ' 'serial interval of the coronavirus disease (COVID-19) and its ' 'gender-specific difference: A data-driven analysis using public ' 'surveillance data in Hong Kong and Shenzhen, China from January 10 to ' 'February 15, 2020. Infect Control Hospital Epidemiol. 2020;10(5):1–8. ' '10.1017/ice.2020.64.', 'DOI': '10.1017/ice.2020.64'}, { 'key': '2022120618374797156_j_med-2022-0569_ref_012', 'doi-asserted-by': 'crossref', 'unstructured': 'Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical ' 'characteristics of imported cases of COVID-19 in Jiangsu Province: a ' 'multicenter descriptive study. Clin Infect Dis. 2020;71(15):706–12. ' '10.1093/cid/ciaa199.', 'DOI': '10.1093/cid/ciaa199'}], 'container-title': 'Open Medicine', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.degruyter.com/document/doi/10.1515/med-2022-0569/xml', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.degruyter.com/document/doi/10.1515/med-2022-0569/pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 12, 6]], 'date-time': '2022-12-06T22:53:26Z', 'timestamp': 1670367206000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.degruyter.com/document/doi/10.1515/med-2022-0569/html'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 1, 1]]}, 'references-count': 12, 'journal-issue': { 'issue': '1', 'published-online': {'date-parts': [[2022, 11, 22]]}, 'published-print': {'date-parts': [[2022, 11, 22]]}}, 'alternative-id': ['10.1515/med-2022-0569'], 'URL': 'http://dx.doi.org/10.1515/med-2022-0569', 'relation': {}, 'ISSN': ['2391-5463'], 'subject': ['General Medicine'], 'published': {'date-parts': [[2022, 1, 1]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit